219 related articles for article (PubMed ID: 22965881)
1. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.
Kohles N; Nagel D; Jüngst D; Stieber P; Holdenrieder S
Tumour Biol; 2012 Dec; 33(6):2401-9. PubMed ID: 22965881
[TBL] [Abstract][Full Text] [Related]
2. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.
Fahmueller YN; Nagel D; Hoffmann RT; Tatsch K; Jakobs T; Stieber P; Holdenrieder S
Int J Cancer; 2013 May; 132(10):2349-58. PubMed ID: 23047645
[TBL] [Abstract][Full Text] [Related]
3. Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.
Wittwer C; Boeck S; Heinemann V; Haas M; Stieber P; Nagel D; Holdenrieder S
Int J Cancer; 2013 Dec; 133(11):2619-30. PubMed ID: 23729200
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy.
Kohles N; Nagel D; Jüngst D; Durner J; Stieber P; Holdenrieder S
Tumour Biol; 2012 Feb; 33(1):33-40. PubMed ID: 21931992
[TBL] [Abstract][Full Text] [Related]
5. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients.
Kohles N; Nagel D; Jüngst D; Durner J; Stieber P; Holdenrieder S
BMC Cancer; 2011 May; 11():202. PubMed ID: 21615953
[TBL] [Abstract][Full Text] [Related]
6. DNase is a prognostic marker in liver cancer patients receiving transarterial chemoembolization therapy.
Kohles N; Nagel D; Jüngst D; Stieber P; Holdenrieder S
Int J Clin Pharmacol Ther; 2013 Jan; 51(1):80-3. PubMed ID: 23260008
[No Abstract] [Full Text] [Related]
7. Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy.
Stoetzer OJ; Fersching DM; Salat C; Steinkohl O; Gabka CJ; Hamann U; Braun M; Feller AM; Heinemann V; Siegele B; Nagel D; Holdenrieder S
Tumour Biol; 2013 Feb; 34(1):81-90. PubMed ID: 22983919
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of serum vascular endothelial growth factor receptor 2 response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization.
Zheng YB; Meng QW; Zhao W; Liu B; Huang JW; He X; Li Y; Hu BS; Lu LG
Med Oncol; 2014 Mar; 31(3):843. PubMed ID: 24442426
[TBL] [Abstract][Full Text] [Related]
9. Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies.
Wirtz TH; Loosen SH; Schulze-Hagen M; Gorgulho J; Kandler J; Joerdens M; Demir M; Mohr R; Bruners P; Kuhl C; Trautwein C; Berres ML; Tacke F; Luedde T; Roderburg C
Clin Transl Sci; 2021 Sep; 14(5):1853-1863. PubMed ID: 33787014
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of serum HIF-1α change following transarterial chemoembolization in hepatocellular carcinoma.
Lin ZH; Jiang JR; Ma XK; Chen J; Li HP; Li X; Wu XY; Huang MS; Lin Q
Clin Exp Med; 2021 Feb; 21(1):109-120. PubMed ID: 33037574
[TBL] [Abstract][Full Text] [Related]
11. Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1.
Sun YD; Zhang H; Chen YQ; Wu CX; Chen ML; Xu HR; Wang S; Liu JZ; Han JJ
BMC Cancer; 2021 Sep; 21(1):1063. PubMed ID: 34583662
[TBL] [Abstract][Full Text] [Related]
12. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
Li L; Gou CY; Li JY; Achakzai R; Li XH
Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
[TBL] [Abstract][Full Text] [Related]
13. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
14. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
[TBL] [Abstract][Full Text] [Related]
15. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
16. Soluble receptor for advanced glycation end-products and progression of airway disease.
Iwamoto H; Gao J; Pulkkinen V; Toljamo T; Nieminen P; Mazur W
BMC Pulm Med; 2014 Apr; 14():68. PubMed ID: 24758342
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Tumor Response Using Alpha-fetoprotein and Des-gamma-carboxy Prothrombin in Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Cerban R; Ester C; Iacob S; Paslaru L; Dumitru R; Grasu M; Constantin G; Popescu I; Gheorghe L
Chirurgia (Bucur); 2018; 113(4):524-533. PubMed ID: 30183583
[TBL] [Abstract][Full Text] [Related]
18. Preoperative chemoembolization in patients with hepatocellular carcinoma undergoing liver transplantation: influence of emergent versus elective procedures on patient survival and tumor recurrence rate.
Stockland AH; Walser EM; Paz-Fumagalli R; McKinney JM; May GR
Cardiovasc Intervent Radiol; 2007; 30(5):888-93. PubMed ID: 17619218
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of vascular endothelial growth factor in both conventional and drug eluting beads transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma in HCV patients.
Farid K; Elalfy H; Abo El-Khair SM; Elgamal H; Besheer T; Elmokadem A; Shabana W; Abed S; Elegezy M; El-Khalek AA; El-Morsy A; Negm A; Elsamanoudy AZ; El Deek B; Amer T; El-Bendary M
Expert Rev Gastroenterol Hepatol; 2020 Dec; 14(12):1203-1214. PubMed ID: 32933325
[TBL] [Abstract][Full Text] [Related]
20. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
